1 | from the rx consultant | | | | | | | 3 | 0.77% |
2 | emails from the rx | | | | | | | 2 | 0.51% |
3 | receive emails from the | | | | | | | 2 | 0.51% |
4 | consent to receive emails | | | | | | | 2 | 0.51% |
5 | consent by submitting this | | | | | | | 2 | 0.51% |
6 | email consent by submitting | | | | | | | 2 | 0.51% |
7 | rxconsultant email consent by | | | | | | | 2 | 0.51% |
8 | from rxconsultant email consent | | | | | | | 2 | 0.51% |
9 | updates from rxconsultant email | | | | | | | 2 | 0.51% |
10 | for updates from rxconsultant | | | | | | | 2 | 0.51% |
11 | to receive emails from | | | | | | | 2 | 0.51% |
12 | and more from the | | | | | | | 1 | 0.26% |
13 | common questions quick facts | | | | | | | 1 | 0.26% |
14 | information on each issue | | | | | | | 1 | 0.26% |
15 | answers let us help | | | | | | | 1 | 0.26% |
16 | you effectively answer your | | | | | | | 1 | 0.26% |
17 | effectively answer your patients’ | | | | | | | 1 | 0.26% |
18 | answer your patients’ common | | | | | | | 1 | 0.26% |
19 | highlevel information on each | | | | | | | 1 | 0.26% |
20 | get highlevel information on | | | | | | | 1 | 0.26% |
21 | line get highlevel information | | | | | | | 1 | 0.26% |
22 | bottom line get highlevel | | | | | | | 1 | 0.26% |
23 | the bottom line get | | | | | | | 1 | 0.26% |
24 | issues the bottom line | | | | | | | 1 | 0.26% |
25 | your patients’ common questions | | | | | | | 1 | 0.26% |
26 | patients’ common questions quick | | | | | | | 1 | 0.26% |
27 | need to brush up? | | | | | | | 1 | 0.26% |
28 | effects and more from | | | | | | | 1 | 0.26% |
29 | easily reference information from | | | | | | | 1 | 0.26% |
30 | reference information from issues | | | | | | | 1 | 0.26% |
31 | information from issues of the | | | | | | | 1 | 0.26% |
32 | rx consultant between daytoday | | | | | | | 1 | 0.26% |
33 | more from the rx | | | | | | | 1 | 0.26% |
34 | between daytoday tasks figurestables | | | | | | | 1 | 0.26% |
35 | daytoday tasks figurestables ataglance | | | | | | | 1 | 0.26% |
36 | tasks figurestables ataglance resources | | | | | | | 1 | 0.26% |
37 | on drugs doses common | | | | | | | 1 | 0.26% |
38 | drugs doses common side | | | | | | | 1 | 0.26% |
39 | doses common side effects | | | | | | | 1 | 0.26% |
40 | common side effects and | | | | | | | 1 | 0.26% |